Read by QxMD icon Read


Yusuke Yoshino, Kazunori Seo, Ichiro Koga, Takatoshi Kitazawa, Yasuo Ota
No abstract text is available yet for this article.
October 21, 2016: Infectious Diseases
R Saito, H Akinobu, R A Shaker, I S Akel, A Assaf-Casals, M Lteif, T Odagiri, R Inaba, N Soudani, S Khafaja, S T Ghanem, M Rajab, Y Shobugawa, G S Dbaibo, H Zaraket
Despite the significant burden of influenza outbreaks, active disease monitoring has been largely absent in the Middle East, including Lebanon. In this study we characterized influenza virus in 440 nasopharyngeal swabs collected from patients with acute respiratory infections during two influenza seasons in Lebanon. Influenza A(H3N2) was dominant in the 2013/14 season while the A(H1N1)pdm09 and B/Yamagata strains were most prevalent in the 2014/15 season. All tested isolates were susceptible to 4 neuraminidase inhibitors (oseltamivir, zanamivir, peramivir and laninamivir)...
October 2, 2016: Eastern Mediterranean Health Journal, la Revue de Santé de la Méditerranée Orientale
Akinobu Hibino, Hiroki Kondo, Hironori Masaki, Yoshinari Tanabe, Isamu Sato, Nobuhiro Takemae, Takehiko Saito, Hassan Zaraket, Reiko Saito
We report five cases of community- and hospital-acquired infections with oseltamivir- and peramivir-resistant A(H1N1)pdm09 viruses possessing the neuraminidase (NA) H275Y mutation during January-February 2016 in Japan. One case was hospitalized and was receiving oseltamivir for prophylaxis. The remaining four cases were not taking antiviral drugs at the time of sampling. These cases were geographically distant and epidemiologically unrelated. The five viruses showed ~300-fold rise in IC50 values against oseltamivir and peramivir, defined as highly reduced inhibition according to the WHO definition...
October 6, 2016: Virus Genes
Yohei Funatsu, Sadatomo Tasaka, Takahiro Asami, Ho Namkoong, Hiroshi Fujiwara, Osamu Iketani, Kazuma Yagi, Yoshifumi Kimizuka, Makoto Ishii, Tomoyasu Nishimura, Haruhiko Ogata, Satoshi Iwata, Tomoko Betsuyaku, Naoki Hasegawa
BACKGROUND: Some subtypes of influenza virus, such as H5N1 and H7N9, cause severe viral pneumonia, for which the intraluminal concentration of the anti-influenza agent in the airway is critical. However, the pharmacokinetics of peramivir, the only available injectable neuraminidase inhibitor formulation, in the airway epithelial lining fluid (ELF) remains unclear. In this study, we aimed to determine the time course of peramivir in the pharyngeal ELF, bronchial ELF, and plasma of healthy volunteers using bronchoscopic microsampling technique...
October 3, 2016: Antiviral Therapy
Ashley Wester, Avinash K Shetty
Influenza virus infection is a major cause of morbidity and mortality in children and adults globally. Seasonal epidemics are common due to the rapid virus evolution, whereas the frequent emergence of antigenic variants can result in pandemics and sporadic/endemic avian influenza virus infections. Although annual vaccination is the mainstay for influenza prevention and control, the use of antiviral agents must be considered for treatment and prophylaxis against influenza. Currently available antiviral drugs include neuraminidase inhibitors (NAIs), adamantanes, and a novel polymerase inhibitor (favipiravir)...
2016: Infection and Drug Resistance
Takuji Komeda, Shingo Ishii, Yumiko Itoh, Masaki Sanekata, Takayoshi Yoshikawa, Jingoro Shimada
Peramivir, the only injectable anti-influenza neuraminidase inhibitor medically available in Japan at present, is considered first-line treatment in patients with high risk factors for influenza exacerbation. We conducted a drug-use investigation of peramivir in inpatients with high risk factors (old age, pregnancy, and underlying disease such as chronic respiratory disease) from January 2010 to March 2013. Data of 772 patients from 124 facilities across Japan were collected; peramivir's safety in 770 patients and effectiveness in 688 patients were examined...
October 2016: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
Chunlong Ma, Fang Li, Rami Ghassan Musharrafieh, Jun Wang
As the number of drug-resistant influenza viruses continues to increase, antivirals with novel mechanisms of action are urgently needed. Among the two classes of FDA-approved antiviral drugs, neuraminidase (NA) inhibitors, oseltamivir, zanamivir, and peramivir, are currently the only choice for the prevention and treatment of influenza virus infection. Due to the antigenic drift and antigenic shift, it will only be a matter of time before influenza viruses become completely resistant to these NA inhibitors...
September 2016: Antiviral Research
Zhengtu Li, Runfeng Li, Jing Li, Hui Xie, Yanbing Hao, Qiuling Du, Tingting Chen, Yimin Li, Rongchang Chen, Zifeng Yang, Nanshan Zhong
BACKGROUND: China-made Peramivir, an anti-influenza neuraminidase inhibitor drug, is manufactured and widely used in China. Although effective if initiated within 48 h of the onset of symptoms, yet we observed that this drug shows an inconclusive efficacy if treatment is delayed in clinical. Thus we evaluated the efficacy of delayed treatment of China-made Peramivir in a mouse model. METHODS: The mouse model of influenza infection was made and Peramivir was administered intravenously for 5 days following infection, and weight loss, lung index, viral shedding and survival rates were monitored...
2016: BMC Infectious Diseases
Toru Kawakami, Yukio Hirabayashi, Fumihiro Kawakami, Rei Isobe, Naoto Kaneko, Yuto Mimura, Toshiro Ito, Kiyoshi Furuta, Mami Shimazaki, Hideyuki Nakazawa, Kiyoshi Kitano
We herein report the case of an 80-year-old man with malignant lymphoma who became persistently infected with influenza A virus. Although he was repeatedly treated with NA inhibitors, such as oseltamivir or peramivir, nasal cavity swab tests for influenza A antigen continued to be positive for more than 2 months. Virological analyses revealed that he was infected with the NA inhibitor-resistant A (H3N2) virus possessing an R292K substitution in the NA protein. These findings suggest that a drug-resistant influenza virus strain might selectively survive antiviral therapy in elderly patients with refractory malignant lymphoma undergoing multiple chemotherapies...
2016: Internal Medicine
Emi Takashita, Seiichiro Fujisaki, Masayuki Shirakura, Kazuya Nakamura, Noriko Kishida, Tomoko Kuwahara, Yukie Shimazu, Takeshi Shimomura, Shinji Watanabe, Takato Odagiri
An influenza A(H1N1)pdm09 virus carrying a G147R substitution in combination with an H275Y substitution in the neuraminidase protein, which confers cross-resistance to oseltamivir and peramivir, was detected from an immunocompromised inpatient in Japan, March 2016. This dual H275Y/G147R mutant virus exhibited enhanced cross-resistance to both drugs compared with the single H275Y mutant virus and reduced susceptibility to zanamivir, although it showed normal inhibition by laninamivir.
June 16, 2016: Euro Surveillance: Bulletin Européen sur les Maladies Transmissibles, European Communicable Disease Bulletin
Masafumi Seki, Ryota Fuke, Nozomi Oikawa, Maya Hariu, Yuji Watanabe
UNLABELLED: We presented three cases of influenza-related severe pneumonia/empyema that occurred in one season. CASE 1: A 76-year-old diabetic man, developed empyema as a result of severe community-acquired pneumonia (CAP) secondary to Haemophilus influenzae, as confirmed on sputum culture. Nasal swab was positive for influenza A antigen. After drainage of empyema, intravenous peramivir and piperacillin/tazobactam were administered for 3 days and 2 weeks, respectively, followed by oral levofloxacin for 2 weeks...
2016: Respiratory Medicine Case Reports
N Lee, P K S Chan, W W S Tam, M C W Chan, G C Y Lui, A K Kwok, F W S Ko, S S S Ng, I M H Yung, R Y K Wong, D S C Hui
An open-label trial on intravenous peramivir was conducted among adult patients hospitalised for influenza-associated lower respiratory tract complications (LRTCs). Virus culture and quantitative reverse transcription PCR (qRT-PCR) were performed serially until Day 10. Peramivir treatment was associated with viral RNA decline as well as culture and RNA negativity, which occurred at rates comparable with those of oseltamivir: by Day 5, viral load decline -2.5 log10 copies/mL [βinteraction -0.071, standard error (SE) 0...
August 2016: International Journal of Antimicrobial Agents
Ming Zhang, Zhan-Zhang Wang, Xiao-Jia Ni, Li-Zhong Li, Yue-Feng Zhang, Hao-Yang Lu, Huan Peng, Wen-Can Huang, Ling-Fang Shen, Ling-Hui Xiong, De-Wei Shang, Yu-Guan Wen
BACKGROUND AND OBJECTIVES: Peramivir, an antiviral agent for intravenous administration, is used to treat progressive influenza in patients with serious complications. The present study was designed to determine the pharmacokinetics of single and multiple intravenous infusions of peramivir in healthy Chinese subjects. METHODS: Single (150, 300 and 600 mg) and multiple (600 mg) doses of peramivir were intravenously administered to 12 healthy Chinese subjects. There was a 7-day washout period between dosing periods...
September 2016: Clinical Drug Investigation
Aeron C Hurt, Terry G Besselaar, Rod S Daniels, Burcu Ermetal, Alicia Fry, Larisa Gubareva, Weijuan Huang, Angie Lackenby, Raphael T C Lee, Janice Lo, Sebastian Maurer-Stroh, Ha T Nguyen, Dmitriy Pereyaslov, Helena Rebelo-de-Andrade, Marilda M Siqueira, Emi Takashita, Masato Tashiro, Danielle Tilmanis, Dayan Wang, Wenqing Zhang, Adam Meijer
The World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza (WHO CCs) tested 13,312 viruses collected by WHO recognized National Influenza Centres between May 2014 and May 2015 to determine 50% inhibitory concentration (IC50) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Ninety-four per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.5% (n = 68) of viruses showed either highly reduced inhibition (HRI) or reduced inhibition (RI) (n = 56) against at least one of the four NAIs...
August 2016: Antiviral Research
Yuuki Kurebayashi, Tadanobu Takahashi, Chihiro Tamoto, Keiji Sahara, Tadamune Otsubo, Tatsuya Yokozawa, Nona Shibahara, Hirohisa Wada, Akira Minami, Kiyoshi Ikeda, Takashi Suzuki
Influenza A and B viruses possess a neuraminidase protein that shows sialidase activity. Influenza virus-specific neuraminidase inhibitors (NAIs) are commonly used for clinical treatment of influenza. However, some influenza A and B viruses that are resistant to NAIs have emerged in nature. NAI-resistant viruses have been monitored in public hygiene surveys and the mechanism underlying the resistance has been studied. Here, we describe a new assay for selective detection and isolation of an NAI-resistant virus in a speedy and easy manner by live fluorescence imaging of viral sialidase activity, which we previously developed, in order to achieve high-efficiency capture of an NAI-resistant virus...
2016: PloS One
Yacine Abed, Xavier Bouhy, Arnaud G L'Huillier, Chantal Rhéaume, Andrés Pizzorno, Miguel Retamal, Clément Fage, Karen Dubé, Marie-Hélène Joly, Edith Beaulieu, Corey Mallett, Laurent Kaiser, Guy Boivin
We recently isolated an influenza A(H1N1)pdm09 E119D/H275Y neuraminidase (NA) variant from an immunocompromised patient who received oseltamivir and zanamivir therapies. This variant demonstrated cross resistance to zanamivir, oseltamivir, peramivir and laninamivir. In this study, the viral fitness of the recombinant wild-type (WT), E119D and E119D/H275Y A(H1N1)pdm09 viruses was evaluated in vitro and in experimentally-infected C57BL/6 mice and guinea pigs. In replication kinetics experiments, viral titers obtained with the E119D and E119D/H275Y recombinants were up to 2- and 4-log lower compared to the WT virus in MDCK and ST6GalI-MDCK cells, respectively...
August 2016: Antiviral Research
Peng-Cheng Wang, Jim-Min Fang, Keng-Chang Tsai, Shi-Yun Wang, Wen-I Huang, Yin-Chen Tseng, Yih-Shyun E Cheng, Ting-Jen Rachel Cheng, Chi-Huey Wong
Peramivir is a potent neuraminidase (NA) inhibitor for treatment of influenza infection by intravenous administration. By replacing the carboxylate group in peramivir with a phosphonate group, phosphono-peramivir (6a), the dehydration and deoxy derivatives (7a and 8a) as well as their corresponding monoalkyl esters are prepared from a pivotal intermediate epoxide 12. Among these phosphonate compounds, the dehydration derivative 7a that has a relatively rigid cyclopentene core structure exhibits the strongest inhibitory activity (IC50 = 0...
June 9, 2016: Journal of Medicinal Chemistry
Malak M Alame, Elie Massaad, Hassan Zaraket
Peramivir is a novel cyclopentane neuraminidase inhibitor of influenza virus. It was approved by the Food and Drug Administration in December 2014 for treatment of acute uncomplicated influenza in patients 18 years and older. For several months prior to approval, the drug was made clinically available under Emergency Use authorization during the 2009 H1N1 influenza pandemic. Peramivir is highly effective against human influenza A and B isolates as well as emerging influenza virus strains with pandemic potential...
2016: Frontiers in Microbiology
Shintaro Suzuki, Akihiko Tanaka, Yosuke Fukuda, Yoshito Miyata, Yasunori Murata, Yasunari Kishino-Oki, Tetsuya Homma, Tsukasa Ohnishi, Hironori Sagara
A 79-year-old man experienced severe chronic obstructive pulmonary disease (COPD) and was receiving treatment for ischemic heart disease. Starting from dizziness and chilliness, he lost consciousness after few days. He was taken to our emergency department. On initial evaluation, he complained of dyspnea and was afebrile with a pulse rate, blood pressure, and respiratory rate of 105 beats/min, 112/98mmHg, and 28 breath/min, respectively. His respiratory sounds were clear and chest radiography did not show any abnormal shadows, but his arterial blood gas examination showed type II respiratory failure...
January 2016: Kansenshōgaku Zasshi. the Journal of the Japanese Association for Infectious Diseases
Yan Zhang, Hainv Gao, Weifeng Liang, Lingling Tang, Yida Yang, Xiaoxin Wu, Liang Yu, Ping Chen, Shufa Zheng, Huilin Ou, Lanjuan Li
BACKGROUND: Since the novel H7N9 avian influenza outbreak occurred in China in 2013, neuraminidase inhibitors (NAIs) such as oseltamivir and peramivir have been used as first-line drugs to treat the influenza virus infection. This study aimed to compare the efficacy of oseltamivir-peramivir combination therapy versus oseltamivir monotherapy. METHODS: A retrospective study of 82 H7N9 confirmed patients was conducted by reviewing medical charts at the First Affiliated Hospital of ZheJiang University in China from April 1, 2013 to Feb 28, 2014...
2016: BMC Infectious Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"